ScripForte Biosciences, Inc. has stopped development of its only clinical asset, FB-401, after it failed in a Phase II study in atopic dermatitis, leaving the company’s future in doubt. With little value
ScripFormer Novartis AG CEO Joe Jimenez and former Novartis Institutes for BioMedical Research Inc. (NIBR) founding president Mark Fishman have brought their drug development expertise to the start-up